CRP and Lymphadenopathy: Our clinical prediction model, incorporating established risk factors (age, CA19-9, CEA, disease duration <1 month, CRP, surgical history, lymphadenopathy), achieved an AUC of 0.83 (95% CI:0.70-0.96), aligning with prior reports (AUC 0.75-0.83) (35–38) while maintaining practical clinical utility.